Based on our finding that the aqueous VEGF level in the A-ROP group was much higher than those in the T-ROP and P-T-1 groups, we propose that the conventional dose of intravitreal anti-VEGF agent might be insufficient to neutralize the intraocular VEGF in eyes with A-ROP, and thus cause the rate of reactivation to remain high even after administering timely anti-VEGF treatment. This evidence concerns the gene VEGFA and retinopathy of prematurity.